spacer
home > news > detailed info
INDUSTRY NEWS AND PRESS RELEASES

Merck to Provide Provantage® End-to-End Development and Manufacturing Services to Y-mAbs for Lead Antibody Compound

Merck Millipore BioMonitoring

Leading science company to provide its product and services to Y-mAbs Therapeutics Inc

  • Includes scale-up and GMP manufacturing of drugs in late-stage development
  • Antibody targets advanced, refractory brain tumors in pediatric patients
Darmstadt, Germany, August 1, 2016 - Merck, a leading science and technology company, will provide its Provantage® End-to-End development and manufacturing services to Y-mAbs Therapeutics, Inc. in support of Y-mAbs' monoclonal antibody in late stage clinical development.

The antibody, targeting refractory leptomeningeal tumor neuroblastoma and diffuse intrinsic pontine glioma, is a potential breakthrough treatment for pediatric patients. Following transfer of Y-mAbs' lead cell line to Merck, services will include scale-up and GMP manufacturing of an antibody currently in late stage clinical development.

"Pediatric brain cancer is an especially challenging therapeutic area that comes with an extreme sense of urgency," said Udit Batra, Member of the Merck Executive Board and CEO, Life Science. "Through our Provantage® services, which offer a templated, nimble approach to development and manufacturing, we expect to accelerate progress of this innovative therapeutic for patients in need."

"Through our agreement with Merck, Y-mAbs takes a major step towards our commitment of making these breakthrough pediatric treatments available to children with advanced and life-threatening cancers,"said Thomas Gad, Y-mAbs' Founder, President and Head of Business Development and Strategy. "We expect to take delivery of cGMP drug product for our planned clinical trials by first half of 2017, and we are committed to making this leading immunotherapy product available to patients with life-threatening diseases worldwide."

Merck's Provantage® End-to-End solution is a comprehensive suite of products and services enabling biopharmaceutical companies to accelerate the progression of molecules into the clinic and toward commercialisation. The turnkey package includes process development, cGMP manufacturing, facility design, equipment for pilot plant production, process and equipment training, technology transfer, equipment qualification and set-up for commercialisation.
phone +49(0)6151 720
web www.merckmillipore.com
email Frankfurter Str. 250 64293 Darmstadt Germany
 
Print this page
Send to a friend
   
spacer
News and Press Releases

Owlstone Medicals ReCIVA Named Invention of the Year in Top 50 Digital Health Awards


More info >>


White Papers

Clinical Trial Labelling – More Than Just Labels

Faubel & Co. Nachfolger GmbH

Deciding which label is best for a particular trial project is not always easy. Labels have become multifunctional tools which are able to convey variable data in different languages, indicate first opening, product originality, support ease of use or blind study drugs. They are no longer used as mere carriers of specified contents.
More info >>

Industry Events

6th Annual Cancer Vaccines Conference

27-28 September 2017, Copthorne Tara Hotel, London UK

Cancer Vaccines 2017: Overcoming hurdles to cancer immune response: Cell therapies, vaccine development and combination therapies. SMi Group is thrilled to present the 6th annual Cancer Vaccines conference, taking place on 27th & 28th September 2017 in Central London, UK. Overcoming hurdles to cancer immune response: Cell therapies, vaccine development and combination therapies.
More info >>

 
©2000-2011 Samedan Ltd.
Add to favourites

Print this page

Send to a friend
Privacy statement